Geneva, July 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600127223) titled 'Keratin 23 as a Pro-fibrotic Molecular Switch in HBV Cirrhosis' on June 26.
Study Type: Observational study
Study Design:
Case-Control study
Primary Sponsor: Shanghai Public Health Clinical Center
Condition:
liver fibrosis
Intervention:
F3: Severe fibrosis:None
F1: Mild fibrosis:None
F4: Cirrhosis:None
F2: Significant fibrosis:None
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-07-01
Target Sample Size: F3: Severe fibrosis:30;F1: Mild fibrosis:30;F4: Cirrhosis:30;F2: Significant fibrosis:30;Healthy control group:20;
Countries of Recruitment:
China
To know more, visit ...